ArticleMedicine2026
Effectiveness and safety of prolonged fenofibrate therapy after the acute phase of hypertriglyceridemic pancreatitis: A long-term retrospective follow-up study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the association of prolonged fenofibrate therapy with recurrent hypertriglyceridemic pancreatitis (HTGP), long-term triglyceride control, and safety during follow-up. This single-center retrospective cohort study included consecutive patients with HTGP diagnosed between January 2023 and December 2024. Patients who survived the index hospitalization and had post-discharge follow-up data were classified into a prolonged fenofibrate group or a control group according to treatment status. Prolonged fenofibrate therapy was defined as documented continuous use for at least 3 months after discharge. The primary outcome was recurrent HTGP. Secondary outcomes included time to 1st recurrence, descriptive crude recurrence proportions at 6, 12, and 24 months, pancreatitis-related readmission, recurrent hospital stay, follow-up triglyceride (TG) control, and safety outcomes. A total of 200 patients were included, including 107 in the prolonged fenofibrate group and 93 controls. Recurrent HTGP occurred in 17 patients (15.9%) in the fenofibrate group and 24 (25.8%) in the control group. Recurrence was numerically lower with fenofibrate, but the crude comparison was not statistically significant (P = .081). Kaplan-Meier analysis showed a similar numerical trend toward better recurrence-free survival (log-rank P = .067). In multivariable Cox regression, prolonged fenofibrate therapy showed a potential association with lower recurrence risk, but the estimate was not statistically significant (adjusted hazard ratio 0.58, 95% confidence interval 0.31-1.07, P = .082). Previous HTGP remained independently associated with recurrence (adjusted hazard ratio 1.96, 95% confidence interval 1.06-3.63, P = .032). Follow-up TG levels were lower in the fenofibrate group (3.9 [2.5-6.2] vs 5.1 [3.0-8.4] mmol/L, P = .012), and more patients achieved TG < 5.6 mmol/L (69.2% vs 53.8%, P = .026). Safety outcomes were comparable between groups. Prolonged fenofibrate therapy after HTGP was associated with improved long-term triglyceride control and an acceptable safety profile. Recurrence-related outcomes consistently favored fenofibrate numerically, but none reached statistical significance. Larger prospective multicenter studies are needed to clarify any effect on recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.